Manufacturing Facilities
Delivering high quality products across the globe

Glenmark has 5 state-of-the-art manufacturing facilities situated in Ankleshwar & Dahej in Gujarat and Aurangabad, Kurkumbh & Mohol in Maharashtra which collectively manufacture over 100 APIs.

The Ankleshwar and Dahej facilities are approved by the U.S. FDA, MHRA UK, KFDA, WHO-GMP and Romanian authorities and cater to the regulated markets of the US, Europe and Japan. The API plants at Kurkumbh and Mohol have state FDA GMP approvals.

Monroe, US

Established in 2015
The facility upon commercialization will manufacture:
  • Oral solids
  • Injectables

Markets

The US

Annual Capacity

Oral solids: 300 – 400 million tablets and capsules annually

Injectables: 20 – 25 million vials and pre-filled syringes

Goa, India

Glenmark has two manufacturing facilities at Goa, India which manufacture:
  • Oral – solids
  • Semi-solids
  • Hormones (oral solids)

ISO 14001: 2004 approved

Regulatory Approvals

  • U.S. FDA
  • MHRA UK
  • ANVISA Brazil
  • TPD Canada
  • MCC South Africa
  • WHO – GMP

Markets

North America, Western Europe

Annual Capacity

Oral solid dosages (OSD): 4000 million tablets and 608 million capsules

Semi-solids: 21 million tubes

Hormone: 400 million tablets

Baddi, India

Commenced operations in 2005.
The facility caters to the production of:
  • Oral solids and liquid orals
  • External preparations like lotions and creams
  • Respiratory segment products

ISO 14001: 2004 approved

Regulatory Approvals

  • U.S. FDA
  • MHRA UK
  • ANVISA Brazil
  • TPD Canada
  • DDA Nepal
  • Ukrainian GMP
  • NDA Uganda
  • FDA Ghana
  • CHMP Kenya
  • MCC South Africa
  • TGA Australia
  • WHO - GMP

Markets

US, Europe, India, semi-regulated markets for specific dosage forms

Annual Capacity

Oral solids: 800 million tablets / capsules

Liquids: 60 million bottles

External preparations: 20 million tubes

Respiratory segment: 15 million units

Nalagarh, India

The plant has three main sections for manufacture of:
  • Oral liquids
  • Semi-solids

ISO 14001: 2004 approved 

Regulatory Approvals

  • ANVISA Brazil
  • NDA Uganda
  • WHO-GMP
  • Local FDA

Markets

India, Asia, Africa

Annual Capacity

Oral liquids: 45 million bottles

Ointments and creams: 45 million units

Lotions: 22 million bottles

Sikkim, India

Established in 2012.
The facility is focused on the manufacturing of:
  • Oral solid dosages

Regulatory Approvals

  • Local FDA

Markets

India

Annual Capacity

Oral Solid dosages : 835 million tablets 

Nashik, India

This was Glenmark’s first manufacturing facility which commenced operations in 1983
The facility is equipped to manufacture products across various dosage forms:
  • Oral solids
  • Liquid orals
  • External creams
  • Powder Shampoos

ISO 14001: 2004 approved 

Regulatory Approvals

  • ANVISA Brazil
  • MOH Ukraine
  • INVIMA Columbia
  • NDA Uganda
  • MOH Nigeria
  • TFDA Tanzania
  • MOH Ethiopia
  • MCC South Africa
  • MOH Congo
  • MOH Oman
  • WHO – GMP

Markets

Exports to emerging markets including , Asia, India, Africa, Russia, CIS, Latin America

Annual Capacity

Oral solids: 270 million tablets / capsules

Oral Liquids: 27 million bottles

External preparations: 50 million units

Powder Shampoo: 20 million units

Indore, India

Commenced operations in 2009
The facility is equipped to manufacture products across various dosage forms:
  • Oral solids
  • Semi-solids
  • Injectables
  • Immunosuppressant

ISO 14001: 2004 approved 

Regulatory Approvals

  • U.S. FDA
  • MHRA UK
  • ANVISA Brazil
  • WHO – GMP

Markets

North America, European regions

Annual Capacity

Oral solid dosages: 1440 million tablets per annum

Buenos Aires, Argentina

The Glenmark manufacturing site at Buenos Aires, Argentina is focused on the manufacturing of Oncology Injectables and is spread across 30,000 sq. ft
  • It serves as a global hub for the manufacturing of Lyophilized and Liquid Injectables used in oncology therapies

Regulatory Approvals

  • U.S FDA
  • MHRA – UK
  • ANMAT Argentina
  • MERCOSUR
  • ANVISA Brazil
  • Gulf GCC

Markets

India, Latin America , ROW

Annual Capacity

Injectables: 3.5 million vials

Vysoke Myto, Czech Republic

The facility manufactures:
  • Solid - orals
  • Semi - solids (Ointments)

Regulatory Approvals

  • Manufacturing licence for medicinal products (Issued by SUKL)
  • Distribution licence for medicinal products (Issued by SUKL)
  • Certificate of GMP Compliance of Manufacturer (Issued by SUKL)
  • Certificate of GMP Compliance of a Manufacturer (Issued by USKVBL)

Markets

European Union countries

Annual Capacity

Oral solid dosages: 144 million tablets

Ointments and creams: 1.5 million tubes

Aurangabad, India

This facility is designed to produce:
  • Cytotoxic oral solid products

Annual Capacity

14 million tablets annually

Quality at Glenmark

Setting new benchmarks through delivery of high quality products across all geographies
Know More